New hope for rare blood disorder: experimental drug TGD001 enters human trials
Disease control
Not yet recruiting
This early-phase trial tests a new drug called TGD001 in about 70 adults with acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) or related blood clotting conditions. The main goal is to check the drug's safety and how the body processes it, while also l…
Phase: PHASE1, PHASE2 • Sponsor: TargED Biopharmaceuticals B.V. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC